CRISPRing the hypertrophic cardiomyopathy: correcting one pathogenic variant at a time
Signal Transduct Target Ther
.
2023 Jun 26;8(1):254.
doi: 10.1038/s41392-023-01526-0.
Authors
Junaid Afzal
1
,
Kshitiz
2
Affiliations
1
Department of Medicine, Division of Cardiology, University of California San Francisco, San Francisco, CA, 94158, USA. junaid.afzal@ucsf.edu.
2
Department of Biomedical Engineering, University of Connecticut Health, Farmington, CT, 06032, USA.
PMID:
37365168
PMCID:
PMC10293165
DOI:
10.1038/s41392-023-01526-0
No abstract available
Publication types
Comment
MeSH terms
CRISPR-Cas Systems*
Cardiomyopathy, Hypertrophic* / genetics
Cardiomyopathy, Hypertrophic* / pathology
Humans